Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
Today MedPharm Holdings announced the successful formulation and development of micro-emulsified, cannabis infused, dissolvable thin strips “Melts,” powered with their proprietary Lipophilic Enhanced Absorption Formulation (LEAF) technology. The oral strip is unique in that it […]
VANCOUVER, Washington, May 15, 2019 — After four years of monotherapy trials, data is now available to submit the long-anticipated pivotal trial for monotherapy to the FDA Trial will include 10 weeks of induction therapy […]
Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
